- Home
- OMCL vs NVCR Comparison
OMCL vs NVCR Comparison
Compare OMCL & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMCL | NVCR |
|---|---|---|
| Founded | 1992 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2000 | 2015 |
Fundamental Metrics
Financial Performance| Metric | OMCL | NVCR |
|---|---|---|
| Price | $37.13 | $17.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $55.83 | $28.08 |
| AVG Volume (30 Days) | 803.4K | ★ 1.7M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $787,309,000.00 | $655,353,000.00 |
| Revenue This Year | $6.77 | $7.72 |
| Revenue Next Year | $5.22 | $6.74 |
| P/E Ratio | $47.87 | ★ N/A |
| Revenue Growth | ★ 9.93 | 8.28 |
| 52 Week Low | $29.06 | $9.82 |
| 52 Week High | $51.84 | $21.45 |
Technical Indicators
Market Signals| Indicator | OMCL | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 40.35 | 55.77 |
| Support Level | $35.57 | $12.85 |
| Resistance Level | $44.52 | $18.48 |
| Average True Range (ATR) | 1.71 | 1.03 |
| MACD | -0.28 | 0.17 |
| Stochastic Oscillator | 23.70 | 38.37 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.